arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

CHINA PHARMA HOLDINGS, INC.

CPHI
$1.12 ▼ -0.04 (-3.45%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
17 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
29
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

CHINA PHARMA HOLDINGS, INC. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). On the positive side, Debt to Equity remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $4.8M
Dividend Yield
Revenue Growth -8.5%
Op. Margin -78.2%
ROIC -11.3%
FCF / Share $0.02
Trailing P/E
Price / Book 0.8x
FCF Yield 1.9%
Debt / Equity 0.06
info Valuation on last close. End-of-day price, Aug 7, 2026.

17-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$4.14M
↓ -8.5%
Net Income Profit after all expenses
$-3.19M
↑ +32.7%
Operating Margin Operating profit as % of sales
-78.2%
↑ +22.9% 3th
FCF / Share Free cash flow per share
$0.02
↑ +108.1%
Long-Term Debt Long-term obligations
$4.30M
↓ -34.3%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
13
Returns
31
Financial Health
49
Cash Quality
21

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 65 quarters